NOVO NORDISK A/S Under the programme initiated 29 April 2016, Novo Nordisk will repurchase B shares for an amount up to DKK 3.5 billion in the period from 29 April 2016 to 3 August 2016.
Since the announcement as of 29 April 2016, the following transactions have been made under the programme:
Number of B shares | Average purchase price | Transaction value, DKK | |
Accumulated, last announcement | - | - | |
29 April 2016 | 162,000 | 366.65 | 59,396,976 |
2 May 2016 | 155,000 | 360.82 | 55,926,356 |
3 May 2016 | 150,000 | 353.73 | 53,059,170 |
4 May 2016 | 152,000 | 351.13 | 53,371,456 |
Accumulated under the programme | 619,000 | 221,753,958 |
On 29 April 2016 Novo Nordisk repurchased 900,000 B shares from employees. The transaction amounted to DKK 0.3 billion and was related to the general employee share programme outside of Denmark from 2013. The shares in this transaction were not part of the Safe Harbour repurchase programme, but were part of the overall DKK 14.0 billion repurchase programme.
Page 2 of 2
With the transactions stated above, Novo Nordisk owns a total of 12,923,645 B shares of DKK 0.20, corresponding to 0.5% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,550,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 14 billion during a 12-month period beginning 3 February 2016. As of 4 May 2016, Novo Nordisk has repurchased a total of 10,765,000 B shares equal to a transaction value of DKK 3,851,308,684.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further informationMedia: | ||
Anne Margrethe Hauge | +45 3079 3450 | amhg@novonordisk.com |
Ken Inchausti (US) | +1 609 786 8316 | kiau@novonordisk.com |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com |
Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com |
Kasper Veje (US) | +1 609 235 8567 | kpvj@novonordisk.com |
Novo Nordisk A/S published this content on 09 May 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 09 May 2016 12:14:04 UTC.
Original documenthttp://www.novonordisk.com/bin/getPDF.2010657.pdf
Public permalinkhttp://www.publicnow.com/view/BD6985F0A480244D0A697C7C5713662B9289743A
